Alnylam to Webcast Presentation at 11th Annual SVB Leerink Global Healthcare ConferenceBusiness Wire • 02/08/22
12 biotech stocks to consider buying now as prospects for the sector brighten this yearMarket Watch • 02/06/22
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial ResultsBusiness Wire • 01/24/22
Alnylam: Biotech To Watch With Potential FDA Approval Of Vutrisiran For Rare DiseaseSeeking Alpha • 01/22/22
Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited DiseaseBenzinga • 01/21/22
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with PolyneuropathyBusiness Wire • 01/21/22
n-Lorem Foundation Partners with Alnylam to Expand Technology Access to RNAi Therapeutics for Patients with Nano-rare DiseasesBusiness Wire • 01/18/22
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual MeetingBusiness Wire • 01/14/22
Soleo Health to Administer OXLUMO™ for the Treatment of Primary Hyperoxaluria Type 1Business Wire • 01/11/22
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional UpdatesBusiness Wire • 01/09/22
Novartis (NVS) Partners With Alnylam for Liver-Targeted TherapiesZacks Investment Research • 01/07/22
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver FunctionBusiness Wire • 01/06/22
Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/03/22
FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad CholesterolBenzinga • 12/23/21
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-CBusiness Wire • 12/22/21
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer's Disease and Cerebral Amyloid AngiopathyBusiness Wire • 12/22/21
Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New GeographiesBusiness Wire • 12/21/21
Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone DiseaseBusiness Wire • 12/20/21
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of GoutBusiness Wire • 12/20/21